Agenus Secures 10 Million Loan from Zydus Backed by MiNK <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Shares
Agenus Inc. has entered into a new Promissory Note Agreement with Zydus Pharmaceuticals $(USA)$ Inc., a subsidiary of Zydus Lifesciences Limited, for up to $10 million. The note, dated October 8, 2025, carries an interest rate of 3.81% per annum and will mature either upon the closing of an Asset Purchase Agreement and Securities Purchase Agreement between the companies or within 10 days of notification if the deals are not consummated. Proceeds from the loan will fund operational expenses for Agenus's Emeryville and Berkeley facilities in the fourth quarter of 2025, with amounts used for these expenses to be forgiven if the transactions close. As collateral, Agenus has pledged 822,910 shares of MiNK Therapeutics, Inc. common stock. The pledge and related control agreement grant certain rights to Zydus in the event of default, and the collateral is expected to be released upon repayment or forgiveness of the note.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-235819), on October 09, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.